Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease

May 30, 2020 By The ASCO Post Staff

Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the CALGB/SWOG 80702 trial of celecoxib plus standard adjuvant therapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX). Adding celecoxib to standard chemotherapy did not significantly improve disease-free or overall survival (Abstract 4003).

Related Content